Better cancer outcomes shouldn't demand bigger budgets—they demand smarter innovation. Reflecting on this year's World Cancer Congress, the path forward is clear: the real cost of cancer isn’t just treatment, but the time stolen from families when care comes too late. By prioritising earlier diagnosis and care closer to home, we don't just free up hospital capacity. We change the equation entirely—turning progress into healthy years of life. #WhatsItWorth #WCC2026 #GlobalHealth

Breast cancer care shouldn't depend on where you live. At this year's World Cancer Congress, the message was clear: regional collaboration is key to ensuring every woman gets the care she deserves, no matter where she lives. By working across borders to bring diagnosis and treatment closer to home, we can turn progress into time—time for women to keep pursuing their dreams. #WhatsItWorth #WCC2026 #GlobalHealth

#MEDIA – We are excited to share positive interim phase III results in IgA nephropathy, a progressive kidney disease that can lead to kidney failure. Read more here 👉 spkl.io/60157TnLZ $ROG $RHHBY

We are pleased to share positive topline Phase II results from our investigational dual GLP-1/GIP receptor agonist in people living with type 2 diabetes, obesity or overweight. Read more here: spkl.io/60197Tn6V $ROG $RHHBY #Obesity

#MEDIA - We are pleased to share that the European Commission (EC) has approved our continuous delivery treatment for adults with neovascular age-related macular degeneration (#nAMD), offering an alternative to standard-of-care eye injections. roche.com/media

#MEDIA –The CHMP has recommended approval of our multiple sclerosis treatment for young people aged 10+ living with relapsing MS in the EU, who have limited options today. 👉spkl.io/60107T3w4 #multiplesclerosis #MS

#MEDIA – We are pleased to announce that the phase III study met its primary endpoint, significantly improving progression-free survival for people with second-line or later relapsed or refractory #FollicularLymphoma #Hematology spkl.io/60157rk3h $ROG $RHHBY

Finding faint molecular clues early is critical for cancer research. Sequencing by expansion (SBX) technology can help researchers detect traces of circulating tumor DNA (ctDNA) to help reveal how tumors grow, change and react to treatment. Learn how: go.roche.com/xgensbx (Research use only) #NGS #Genomics #Innovation #MakeSpaceWithSBX #RocheSBX

#MEDIA – We’re pleased to share positive Phase III data from our collaborator MediLink’s study in Chinese patients with relapsed small-cell #LungCancer, being presented at #WCLC26. Read more here: spkl.io/60187rEA2 $ROG $RHHBY

#MEDIA – At #APVRS2026, we're pleased to share new two-year data for our treatment in patients with PCV, a severe sub-type of nAMD – the leading cause of vision loss in people over 60. roche.com/media

Sleep should be a time of rest, not a time of risk. "I think predictive technology gives us a lot more than just a safe sleep and better predictions. It also means more quality of life and not using this energy for the diabetes, but actually using it for things that matter to us." Discover how AI-enabled predictive algorithm turns data into actionable insights for navigating everyday life: roche.com/stories/diabetes-m… #DiabetesCare #DigitalHealth #NightLowPredict #Innovation #Roche

#MEDIA – We are pleased to share that the CHMP has recommended approval of our continuous delivery treatment for adults with neovascular age-related macular degeneration (#nAMD) - the leading cause of blindness in people over 60. 👉 spkl.io/60127J2hs

Roche’s sequencing by expansion (SBX) technology is transforming DNA sequencing! By converting nucleotide bases into long molecules before it passes through microscopic pores, it scales up molecular signals into digital data.✨ #Biotech #Innovation go.roche.com/xnanosbx (Roche's sequencing technology is currently for research use only.)

#MEDIA – We are pleased to announce that the U.S. FDA has accepted Roche’s supplemental Biologics License Application, with priority review, in primary #MembranousNephropathy Read more here 👉 spkl.io/60167yjsi $ROG $RHHBY

The first fully automated diagnostic solution to identify the most severe form of viral hepatitis is finally here, helping clinicians address the urgent need for a consistent, widely accessible solution. roche.com/media $RHHBY $ROG Available in countries accepting the CE mark. For in vitro diagnostic use. Please consult the Instructions for Use for complete product information, including intended use and limitations.

We're at #AAIC26! Come by booth to speak to our team about the latest advancements in Alzheimer’s. We look forward to meeting you! 👋